Nicklas Rosendal - Prostatype Genomics Communications Director

All Insiders . Sweden . 
Stock . Prostatype Genomics AB . Stakeholders . Insider . Nicklas Rosendal
PROGEN Stock  SEK 0.57  0.01  1.72%   

Insider

Nicklas Rosendal is Communications Director of Prostatype Genomics AB
Phone46 08 20 87 00
Webhttps://www.prostatypegenomics.com

Prostatype Genomics Management Efficiency

The company has return on total asset (ROA) of (0.3871) % which means that it has lost $0.3871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7024) %, meaning that it generated substantial loss on money invested by shareholders. Prostatype Genomics' management efficiency ratios could be used to measure how well Prostatype Genomics manages its routine affairs as well as how well it operates its assets and liabilities.
Prostatype Genomics AB has accumulated 866.67 K in total debt with debt to equity ratio (D/E) of 0.07, which may suggest the company is not taking enough advantage from borrowing. Prostatype Genomics has a current ratio of 3.04, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Prostatype Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, Prostatype Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Prostatype Genomics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Prostatype to invest in growth at high rates of return. When we think about Prostatype Genomics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Tatsiana LobovkinaFluicell AB
48
Anders WeilandtChordate Medical Holding
62
Jan HermanssonChordate Medical Holding
67
Gavin JeffriesFluicell AB
43
Peter WarthoeQlife Holding AB
56
Thomas WarthoeQlife Holding AB
56
Matija RojnikFluicell AB
39
Grith Hagel2cureX AB
64
Kasper RousoeQlife Holding AB
N/A
Helena ThediusChordate Medical Holding
47
Niklas LindecrantzChordate Medical Holding
55
Kenneth Johansen2cureX AB
47
Mattias MScStayble Therapeutics AB
44
Fernando Andreu2cureX AB
59
Victoire ViannayFluicell AB
48
Thomas MScStayble Therapeutics AB
71
Jan LindbergChordate Medical Holding
67
Andreas MScStayble Therapeutics AB
35
Mark Gray2cureX AB
53
Anders LehmannStayble Therapeutics AB
66
Jakob LindQlife Holding AB
N/A
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. The company was founded in 2007 and is based in Solna, Sweden. Prostatype Genomics is traded on Stockholm Stock Exchange in Sweden. Prostatype Genomics AB (PROGEN) is traded on Stockholm Exchange in Sweden and employs 6 people.

Management Performance

Return On Equity-0.7
Return On Asset-0.39

Prostatype Genomics Leadership Team

Elected by the shareholders, the Prostatype Genomics' board of directors comprises two types of representatives: Prostatype Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Prostatype. The board's role is to monitor Prostatype Genomics' management team and ensure that shareholders' interests are well served. Prostatype Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Prostatype Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Nicklas Rosendal, Communications Director
Joakim Soderin, Chief Auditor
Emelie Berglund, Chief Officer
Fredrik Persson, CEO MD
Michael Winklerfelt, CFO COO

Prostatype Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Prostatype Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.7
Return On Asset-0.39
Operating Margin(23.61) %
Current Valuation20.62 M
Shares Outstanding22.86 M
Shares Owned By Insiders1.00 %
Shares Owned By Institutions13.47 %
Price To Book1.14 X
Price To Sales34.59 X
Revenue10 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Other Information on Investing in Prostatype Stock

Prostatype Genomics financial ratios help investors to determine whether Prostatype Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prostatype with respect to the benefits of owning Prostatype Genomics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY